Study of Ivonescimab with TAS-102 for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs – ivonescimab (a type of immunotherapy) and TAS-102 (a chemotherapy) – for people with advanced colorectal cancer that has not responded to at least two prior chemotherapies. The goal is to see if this new combo can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- Your colorectal cancer is MSS or pMMR (a type of genetic testing).
- You have already tried at least two standard chemotherapy treatments for advanced colorectal cancer, and either the cancer continued to grow or you could not tolerate the side effects.
- You have at least one tumor that can be measured on a CT or MRI scan.
- You feel well enough to be up and about (able to do light housework or office work) – ECOG 0 or 1.
- Your major organs (kidneys, liver, bone marrow) are working well enough, based on routine blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests whether adding a new drug called ivonescimab to standard chemotherapy helps shrink advanced colon cancer before surgery. It may improve the chances of removing all the cancer and reduce the risk of it coming back.
This trial compares two combinations of drugs for people with a certain type of advanced colorectal cancer that has progressed after initial treatment. It aims to see if one combination works better than the other, potentially offering a new option for second-line therapy.
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
This trial is testing a combination treatment for colorectal cancer that has spread to other parts of the body and cannot be removed with surgery. The treatment includes a drug called Ivosidenib, chemotherapy, and radiation therapy. It aims to see if this combination can help shrink or control the cancer.
This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.
Hear when a new MSS/pMMR Type Metastatic Colorectal Adenocarcinoma Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.